Published in Br J Cancer on January 29, 2015
ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro. Oncotarget (2015) 0.81
Dynamics of Protein Expression Reveals Primary Targets and Secondary Messengers of Estrogen Receptor Alpha Signaling in MCF-7 Breast Cancer Cells. Mol Cell Proteomics (2016) 0.77
The predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer. Cancer Sci (2017) 0.75
Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. J Zhejiang Univ Sci B (2017) 0.75
Active nuclear transcriptome analysis reveals inflammasome-dependent mechanism for early neutrophil response to Mycobacterium marinum. Sci Rep (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
NIH Image to ImageJ: 25 years of image analysis. Nat Methods (2012) 84.41
Immunity, inflammation, and cancer. Cell (2010) 28.27
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A (2006) 4.51
NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol (2009) 3.86
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
Extracting biological meaning from large gene lists with DAVID. Curr Protoc Bioinformatics (2009) 2.88
DNA-binding specificity of NGFI-A and related zinc finger transcription factors. Mol Cell Biol (1995) 2.78
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47
Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol (2011) 2.45
Prostate cancer epidemiology in the United States. World J Urol (2012) 2.16
Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology (2009) 2.05
Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer (2004) 1.98
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol (2014) 1.89
Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol (2001) 1.86
Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol (2005) 1.82
The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol (2011) 1.71
Tumor-elicited polymorphonuclear cells, in contrast to "normal" circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl Acad Sci U S A (1989) 1.68
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol (2011) 1.55
In silico estimates of tissue components in surgical samples based on expression profiling data. Cancer Res (2010) 1.50
Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate (1998) 1.48
Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol (2007) 1.43
Prostate growth and inflammation. J Steroid Biochem Mol Biol (2007) 1.33
Is EGR1 a potential target for prostate cancer therapy? Future Oncol (2009) 1.29
IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene (2011) 1.21
Activation and function of immediate-early genes in the nervous system. Biochem Cell Biol (2011) 1.20
New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol (2012) 1.19
Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol (2009) 1.17
Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol (2004) 1.11
The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J Clin Endocrinol Metab (1996) 1.07
Early growth response proteins EGR-4 and EGR-3 interact with immune inflammatory mediators NF-kappaB p50 and p65. J Cell Sci (2005) 1.06
Early growth response transcription factors and the modulation of immune response: implications towards autoimmunity. Autoimmun Rev (2009) 1.04
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2011) 1.00
Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells. Endocr Relat Cancer (2010) 0.93
Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor. Endocr Relat Cancer (2007) 0.91
Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer. PLoS One (2013) 0.90
Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin North Am (2008) 0.90
Decreased EGR3 expression is related to poor prognosis in patients with gastric cancer. J Mol Histol (2013) 0.87
The epidemiology of prostate cancer--with a focus on nonsteroidal anti-inflammatory drugs. Hematol Oncol Clin North Am (2006) 0.83
Cyclooxygenase-2: a therapeutic target for prostate cancer. Clin Genitourin Cancer (2005) 0.82